Archives
-
DiscoveryProbe™ FDA-approved Drug Library: Enabling Function
2026-06-13
Explore how the DiscoveryProbe FDA-approved Drug Library empowers mechanistic drug repurposing, illustrated by the breakthrough identification of sulfasalazine for sarcopenia. This in-depth analysis reveals practical assay strategies and unique screening advantages.
-
Elevating Translational Research: Mechanistic DNA Synthesis
2026-06-12
This article unites new mechanistic evidence on dNTP formulation with cutting-edge intracellular delivery research, providing actionable guidance for translational scientists. By bridging core molecular biology workflows with recent findings on lipid nanoparticle trafficking, we illuminate how the APExBIO 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture enables reproducible, high-fidelity DNA synthesis that supports the next wave of therapeutics and diagnostics.
-
Ibrexafungerp Efficacy Against Fluconazole-Resistant C. auri
2026-06-12
This study demonstrates that ibrexafungerp exhibits potent in vitro activity and significant in vivo efficacy against fluconazole-resistant Candida auris, even when treatment is delayed. Its unique mechanism and oral administration profile position it as a valuable antifungal option for multidrug-resistant invasive candidiasis.
-
Cholesterol Impedes Intracellular Trafficking of Lipid Nanop
2026-06-11
This study demonstrates that elevated cholesterol content within lipid nanoparticles (LNPs) significantly hinders their intracellular trafficking and reduces cargo delivery efficiency. The findings refine our understanding of LNP composition optimization for nucleic acid delivery, with practical implications for the design of gene therapy and mRNA vaccine carriers.
-
Innovative In Vitro Approaches to Assess Anti-Cancer Drug Re
2026-06-11
Schwartz's dissertation advances the evaluation of anti-cancer drugs by dissecting the distinct contributions of growth inhibition and cell death in vitro. This distinction enhances mechanistic insight for targeted therapies, especially in kinase-driven cancers, and informs the optimization of experimental assays.
-
Cholesterol Hinders Lipid Nanoparticle Trafficking in Cells
2026-06-10
A 2025 study reveals that elevated cholesterol in lipid nanoparticles (LNPs) promotes their trapping in peripheral early endosomes, thereby impeding intracellular trafficking and lowering nucleic acid delivery efficiency. These findings refine our understanding of LNP formulation and highlight the importance of cholesterol balance for optimal genetic cargo delivery.
-
ECL Western Blotting Substrate: Protocol and Technical Guida
2026-06-10
ECL Western Blotting Substrate (SKU K2187) provides a sensitive, nonradioactive solution for protein detection by chemiluminescence in Western blot assays. It is best suited for workflows requiring horseradish peroxidase detection and is not compatible with fluorescent or radioisotopic methods. Researchers in molecular biology, cancer biology, and signal transduction pathway research can integrate this substrate without additional assay optimization.
-
Benzyl-activated Streptavidin Magnetic Beads in Cell Death A
2026-06-09
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) streamline the capture and analysis of biotinylated molecules in advanced cell death and protein interaction workflows. Their hydrophobic, BSA-blocked surface ensures high specificity and reproducibility, especially in early apoptosis detection and complex sample purification.
-
ECL Western Blotting Substrate: Technical Use and Workflow G
2026-06-09
ECL Western Blotting Substrate (SKU K2187) addresses the need for sensitive, nonradioactive detection of HRP-labeled proteins via chemiluminescence. It is suitable for Western blot assays in molecular biology, cancer biology, and signal transduction pathway research, but is not compatible with fluorescent or radioisotopic detection methods. Researchers should use this substrate only in established chemiluminescent protein detection workflows.
-
Tirbanibulin Suppresses HPV Oncoproteins via Src-MEK Pathway
2026-06-08
This study demonstrates that tirbanibulin, a synthetic antiproliferative agent, significantly downregulates expression of HPV oncoproteins and related signaling proteins in HeLa cells. By targeting the Src-MEK pathway, tirbanibulin impairs cell proliferation and enhances apoptosis, offering mechanistic insight into its potential for HPV-associated cancer therapies.
-
AP1903: Precision FKBP-Binding Ligand for Conditional Cell A
2026-06-08
AP1903 enables researchers to achieve finely tuned, reversible control of FKBP fusion proteins, empowering high-throughput studies in apoptosis pathways and conditional cell ablation. Its nanomolar potency makes it a standout choice for multiplexed workflows and sophisticated dimerization assays where precise signal modulation is critical.
-
AP20187: Transforming Conditional Gene Activation for Transl
2026-06-07
This thought-leadership article explores how AP20187, a synthetic chemical inducer of dimerization, is revolutionizing conditional gene activation in translational research. Through mechanistic insight, recent advances in cancer signaling, and strategic protocol guidance, we position AP20187 at the forefront of regulated cell therapy innovation—bridging the gap between molecular design and clinical translation.
-
GLI2 Drives Tumor Immune Evasion via WNT and Prostaglandin S
2026-06-06
This study identifies GLI2 as a central regulator of tumor immune evasion and resistance to immunotherapy, acting through coordination of WNT ligand production and prostaglandin signaling. The findings outline mechanistic links between mesenchymal transformation, immunosuppressive microenvironments, and checkpoint blockade resistance, informing potential combined therapeutic strategies.
-
Iterative Discovery of TAS2R14 Ligands Using FDA-Approved Li
2026-06-05
This study demonstrates an iterative, combined computational and experimental approach to identify new agonists and antagonists for the promiscuous GPCR TAS2R14, employing high-throughput screening of FDA-approved drug libraries and structure refinement. The findings reveal significant expansion of known TAS2R14 modulators and highlight a framework applicable to other challenging GPCR targets.
-
AP20187: Enabling Precision Control in Conditional Gene Ther
2026-06-05
Explore how AP20187, a potent chemical inducer of dimerization from APExBIO, is transforming translational research by delivering tunable, reversible control of fusion protein signaling. This thought-leadership article bridges mechanistic understanding and strategic guidance, highlighting AP20187’s unique value for regulated cell therapy and complex disease modeling, and providing actionable protocol insights for researchers advancing the frontiers of gene therapy and metabolic research.